NCT06432322 - (GluEsk) Glutamate and Esketamine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

March 26, 2025

Study Completion Date

March 26, 2025

Conditions

Depression

Interventions

DRUG

Esketamine nasal spray

Nasal spray solution, 56mg (28mg per nostril), intranasal

OTHER

Placebo

Nasal spray solution, 0.9% NaCl, intranasal

Trial Locations (1)

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford

All Listed Sponsors

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Oxford

OTHER